Zhang Xiao, Xu Dong, Zhang Rui, Wang Hui, Yang Gangyi
Department of Endocrinology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400037, China.
Department of Endocrinology, Xinqiao Hospital, Army Medical University, Chongqing, 400010, China.
Osteoporos Int. 2025 Sep 8. doi: 10.1007/s00198-025-07636-5.
Diabetes and osteoporosis are common chronic diseases worldwide, and there is a complex pathological relationship between the two. Due to hyperglycemia, insulin resistance, and accumulation of advanced glycation end products (AGEs), diabetic patients often show a higher risk of fractures. At the same time, chronic low-grade inflammation and oxidative stress caused by diabetes also play an important role in the occurrence of osteoporosis, disrupting the balance of bone remodeling. This review deeply explores the effects of chronic inflammation caused by diabetes on the function of osteoblasts and osteoclasts, analyzes the mechanism of increased bone resorption and decreased bone formation during bone remodeling, and summarizes potential therapeutic intervention strategies, such as anti-inflammatory therapy, bone remodeling promoters, and the application prospects of new targeted drugs.
糖尿病和骨质疏松症是全球常见的慢性疾病,二者之间存在复杂的病理关系。由于高血糖、胰岛素抵抗以及晚期糖基化终末产物(AGEs)的积累,糖尿病患者通常骨折风险更高。同时,糖尿病引起的慢性低度炎症和氧化应激在骨质疏松症的发生中也起重要作用,破坏了骨重塑的平衡。本综述深入探讨糖尿病引起的慢性炎症对成骨细胞和破骨细胞功能的影响,分析骨重塑过程中骨吸收增加和骨形成减少的机制,并总结潜在的治疗干预策略,如抗炎治疗、骨重塑促进剂以及新型靶向药物的应用前景。